Concurrent Pemetrexed With EGFR-TKI Slows the Accumulation of De Novo Mutations During In Vitro Exposure.

Abstract excerpt

BACKGROUND/AIM: Resistance to targeted therapy limits its efficacy in non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. Although concurrent administration of pemetrexed (PEM) and EGFR-tyrosine kinase inhibitors (TKIs) has yielded clinical benefits, it remains unclear whether concurrent PEM influences de novo mutations in the EGFR-TKI therapy. To address this gap, we...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acrylamides
• Share to Aniline Compounds